证券代码：000952 证券简称：广济药业 湖北广济药业股份有限公司投资者关系活动记录表 | --- | --- | |----------|--------------------------------------------------------------| | | | | | □ 特定对象调研□分析师会议 | | 投资者关 | □ 媒体采访√业绩说明会 | | 系活动类 | □ 新闻发布会□路演活动 | | 别 | □现场参观 | | | □ 其他 | | 参与单位 | 西南证券、华宝兴业基金、浦银安盛基金、长信基金、华富基金、上 | | 名称及人 | 投摩根、国海富兰克林基金、信诚基金、诺安基金、海富通基金、银 | | 员姓名 | 河基金 | | 时间 | 2016 年 3 月 2 日 14：00-17:00 | | 地点 | 上海香格里拉大酒店 | | 上市公司 | | | 接待人员 | 董事会秘书安江波 | | 姓名 | | 编号：2016-1 | --- | --- | |----------|------------------------------------------------ ...

证券代码：000952 证券简称：广济药业 编号：2017-4 湖北广济药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-------------------|-------------------------------|---------|---------------------------------------------|-------| | | □ 特定对象调研 □分析师会议 | | | | | 投资者关 系活动类 | □ 媒体采访 √业绩说明会 | | | | | 别 | □ 新闻发布会 □路演活动 | | | | | | □ 现场参观 □其他 | | | | | | | | 招商银行 谭文萍 深圳鑫大通资本 李树军 | | | | | | 西南证券 陈继业 中竣信合 黄科荣 | | | | | | 拉萨康为投资 杨立国 博时基金 苏永超 | | | | | | 广东民营投资 吕金平 清科集团 董姗姗 | | | 参与单位 | | | 易同投资 詹恒祎 久银投资 郭姗 | | | 名称及人 员姓名 | | | 华泰证券 王可道 广发资管 ...

证券代码：000952 证券简称：广济药业 编号：2017-5 湖北广济药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------|----------------------------|---------------------------------|-------| | | □ 特定对象调研 □分析师会议 | | | | 投资者关 系活动类 | □ 媒体采访 √业绩说明会 | | | | 别 | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 □其他 | | | | | | 天安财险 王 喆 华泰保险 赵旭照 | | | 参与单位 | | 东吴证券 许汪洋 方正证券 田俊峰 | | | 名称及人 员姓名 | | 亚宝药业 丁 璇 中融基金 杜 伟 | | | | | 九州证券 叶 娟 九州证券 胡双丁 | | | 时间 | 2017 年 3 月 23 | 15:00-17:00 | | | 地点 | 武汉宏城金都七楼会议室 | | | | 上市公司 | | | | | 接待人员 | 董事会秘书安江波 | | | | ...

证券代码：000952 证券简称：广济药业 编号：2017-1 | --- | --- | --- | --- | --- | |-------------------|------------------|--------------------------|-------------------------------------|--------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | | | 投资者关 系活动类 | □ | 媒体采访 □业绩说明会 | | | | 别 | □ | 新闻发布会 □路演活动 | | | | | □ 现场参观 □其他 | | | | | 参与单位 | | | | 由约调研数据平台按行业、自选股定向精准邀请，共有 33 位机 | | 名称及人 | | | | 构投资者及行业研究员报名参加广济药业机构投资者交流会： | | 员姓名 | | | 华银精治资本 谭龙 马良资本 邱君 | | | | | | | | | | | | 恒益天泽资本 帅金晓 马良资本 向 ...

证券代码：000952 证券简称：广济药业 编号：2017-2 | --- | --- | --- | --- | |-----------|------------------------------------|------------------|--------------------------| | | | | | | 投资 | □ 特定对象调研 □分析师会议 | | | | 者关 | □ 媒体采访 √业绩说明会 | | | | 系活 动类 | □ 新闻发布会 □路演活动 | | | | 别 | □ 现场参观 □其他 | | | | 参与 | 由机会宝平台和平安证券组织，共有 | 21 | 位机构投资者及行业研究员 | | 单位 | 报名参加广济药业机构投资者交流会： | | | | 名称 | 湖南金证 | 久富投资 | 罗云涛 | | 及人 | | | | | 员姓 | 湖南金证 | 诚朴投资 | 应巧 | | 名 | 中信证券 | 中邮证券 | 鲁春娥 | | | 鑫乐达投资 | 基石投资 | 杜志鑫 | | | 浙商证券资管 | 上海名禹资产管理 | 王益聪 | | | 上海源阡资产管理 | ...

证券代码：000952 证券简称：广济药业 编号：2017-3 湖北广济药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------|----------------------|--------------------------------------------------------|-----------| | | □ | 特定对象调研 □分析师会议 | | | 投资者关 系活动类 | □ | 媒体采访 √业绩说明会 | | | 别 | □ | 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | | 参与单位 | | 由约调研数据平台按行业、自选股定向精准邀请，共有 | 15 位机 | | 名称及人 | | 构投资者及行业研究员报名参加广济药业机构投资者交流会： | | | 员姓名 | 财富证券研究发展中心 | | 陈博 | | | | 湖北乾涌股权投资基金管理有限公司 | 翁力 | | | 太平洋证券研究院 | | 孙立金 | | | | 武汉信用基金管理有限公司 | 梅琛 | | | 国海证券研究所 | ...

证券代码：000952 证券简称：广济药业 湖北广济药业股份有限公司投资者关系活动记录表 编号：2019-001 | --- | --- | --- | --- | |---------------------------|---------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | | 投资者关系活 | √ | 媒体采访 □业绩说明会 | | | 动类别 | □ | 新闻发布会 □路演活动 | | | | √ 现场参观 | □ 其他 | | | | 召开 2018 | | 年度股东大会，邀请现场 ...

证券代码：000952 证券简称：广济药业 湖北广济药业股份有限公司投资者关系活动记录表 编号：2018-1 | --- | --- | --- | |--------------|------------------------|------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系活 | □ | 媒体采访 □业绩说明会 | | 动类别 | □ 新闻发布会 □路演活动 | | | | √ 现场参观 □其他 | | | 参与单位名称 | | 武汉圣诚金服信息技术有限公司 | | 及人员姓名 | 罗丽娟 贺畅玲 | | | 时 间 | 2018 年 10 月 | 26 日 14：00-17:00 | | 地 点 | 广济药业 | | | 上市公司接待 | | | | 人员姓名 | | | | | | 董事长安靖、证券事务代表郑彬 | | --- | --- | |------------------------|----------------------------------------------------------------- ...

湖北广济药业股份有限公司 2022 年第三季度报告 □是 否 证券代码：000952 证券简称：广济药业 公告编号：2022-078 湖北广济药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 161,605,183.84 | 5.61% | 674,481,519.91 | 41.60% | | 归属于上市公司股东 | -4,788,962.79 | -133.11% | 19,907,20 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥512,876,336.07, representing a 58.63% increase compared to ¥323,308,914.09 in the same period last year[21]. - The net profit attributable to shareholders decreased by 58.65% to ¥24,696,168.47 from ¥59,719,564.69 year-on-year[21]. - The net profit after deducting non-recurring gains and losses fell by 60.55% to ¥13,086,836.87 compared to ¥33,173,669.00 in the previous year[21]. - Basic earnings per share decreased by 59.50% to ¥0.0703 from ¥0.1736 year-on-year[21]. - Total revenue for the period reached ¥512,876,336.07, a year-on-year increase of 58.63% compared to ¥323,308,914.09[46]. - The pharmaceutical manufacturing sector generated ¥320,091,847.81, accounting for 62.41% of total revenue, with a slight increase of 3.45% year-on-year[46]. - The pharmaceutical wholesale and related services segment saw a dramatic increase of 1,288.50%, reaching ¥192,784,488.26, up from ¥13,884,380.35[46]. - The company reported a net loss of 1.86 million yuan from its subsidiary Guangji Pharmaceutical (Mengzhou) due to adverse market conditions[69]. Cash Flow and Investments - The net cash flow from operating activities was negative at -¥14,598,814.46, a decline of 130.53% from ¥47,812,008.22 in the same period last year[21]. - The cash flow from investing activities was -¥75,262,443.05, a 66.26% increase compared to the previous year, due to higher investments in the construction of a 1,000-ton vitamin B12 comprehensive utilization project[44]. - The company has approved the use of up to 120 million yuan of idle raised funds for cash management, ensuring daily operations and fund safety[68]. - The company reported a decrease in tax refunds received, totaling CNY 1,226,198.21 compared to CNY 3,693,170.31 in the previous year[168]. - The net increase in cash and cash equivalents for the period was a decrease of CNY 2,388,804.06, contrasting with an increase of CNY 111,383,222.59 in the previous year[169]. Assets and Liabilities - Total assets increased by 7.96% to ¥2,211,898,530.61 from ¥2,048,896,426.54 at the end of the previous year[21]. - The company's total liabilities decreased slightly to CNY 751,875,122.23 from CNY 598,092,478.58, indicating a reduction of approximately 25.6%[155]. - The company's long-term borrowings increased significantly to CNY 224,355,000.00 from CNY 34,450,000.00, indicating a growth of approximately 551.5%[155]. - The total amount of guarantees approved for the company during the reporting period is 120 million yuan, with an actual occurrence of 0[122]. Research and Development - Research and development expenses increased by 57.76% to ¥29,323,266.68, reflecting investments in optimizing fermentation processes and developing pharmaceutical formulations[44]. - The company is enhancing its R&D capabilities with the completion of a new pharmaceutical technology laboratory expected by the end of 2022, focusing on multiple product developments[73]. - The company has allocated 21 million yuan for research and development in new technologies[172]. Market and Competition - The company faced a decline in sales volume of high-content vitamin B2 and 80% feed-grade vitamin B2 products due to regional COVID-19 outbreaks and increased market competition[34]. - The company is facing market risks due to oversupply in the B vitamin sector, leading to prolonged low prices for its main products VB2 and VB6[71]. - The company is exploring potential mergers and acquisitions to enhance its market share[172]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has implemented a long-term incentive plan, completing the first grant of restricted stock, aligning the development goals with the management team and key personnel[41]. - The company actively engages with shareholders and investors, enhancing information transparency and communication channels[98]. - The total number of ordinary shareholders at the end of the reporting period was 30,660[139]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[82]. - Hubei Guangji Pharmaceutical Co., Ltd. reported that all environmental protection facilities are operating normally and effectively, with no exceedances in pollutant emissions[84]. - The company has actively participated in community support activities, including a 40,000 CNY investment for sewer system improvements to address wastewater issues for local residents[99]. - The company has established a diverse welfare system for employees, ensuring compliance with labor laws and promoting a harmonious labor relationship[98]. Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[172]. - Future guidance suggests a projected revenue growth of 10% for the next fiscal year[172]. - The company aims to improve operational efficiency through strategic initiatives and cost management[172].